Target intelligence / Profile preview

Collagen matrix of dermis

Molecular classification
Other (structural extracellular matrix component), Protein complex (fibrous), Not a canonical drug target (see comments below)
01

Overview

The collagen matrix of the dermis refers to the dense, fibrous network of collagen proteins (primarily types I and III) that forms the major structural component of the skin’s dermis layer[1][3][4][5][7]. This matrix provides tensile strength, elasticity, and serves as a scaffold for cell adhesion, migration, and proliferation, thereby playing a crucial role in wound healing, skin integrity, and tissue homeostasis[1][2][4]. The matrix is synthesized mainly by fibroblasts and remodeled through a balance of synthesis and enzymatic degradation[1][2]. Dysregulation of the dermal collagen matrix is implicated in pathological conditions such as fibrosis, chronic wounds, skin aging, and certain connective tissue disorders[2][4]. It is not a classic drug target like a receptor or enzyme but is a critical component for structural integrity and is the focus of therapies aimed at wound healing, fibrosis prevention, and cosmetic interventions[2][4]. While enzymes and agents can modify this matrix, "collagen matrix in dermis" is not itself a distinct, single molecular target, but a heterogeneous structural entity[1][3][4].

Other names
Dermal collagen matrixDermal extracellular collagen matrixCollagen fibers of dermis
02

Mechanism of action

Enzymatic degradation (e.g., collagenase breaks down collagen) - Modulation of remodeling (aimed at fibrosis, scar prevention) - Structural augmentation/repair (for dermal fillers/scaffolds) - Not typically a “drug target” in classical pharmacology

03

Biological functions

Structural supportTensile strength to skinScaffold for cell adhesion, proliferation, and migrationRegulation of cell signaling (indirect, via ECM)Wound healing
04

Disease associations

Skin agingScarring and fibrosis (e.g., keloids)Impaired wound healing (e.g., chronic wounds)Scleroderma and connective tissue diseases
05

Safety considerations

Immunogenicity of exogenous collagen (if used therapeutically)Impaired remodeling or excessive breakdown can lead to poor healing, chronic wounds, or excessive scarring (fibrosis)Allergic reactions to collagen-based dermal implants or fillers
06

Interacting drugs

Collagenase (degrades collagen)

3 more in the full profile.

07

Biomarkers

Collagen type I and III levels (biopsies, stains, or blood markers)Breakdown products (e.g., hydroxyproline)Imaging of dermal matrix (scarring, fibrosis)

Beyond the preview

Go deeper on Collagen matrix of dermis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Collagen matrix of dermis.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call